华氏巨球蛋白血症研究进展

华氏巨球蛋白血症（WM）是一种B细胞淋巴增殖性疾病，目前仍然难以治愈。近年来，在基础研究方面，针对WM患者依鲁替尼耐药的机制有了进一步探索，二代测序、靶向测序等新技术的应用促进了疾病发生及预后方面的研究进展。在临床研究方面，传统药物的回顾性亚组分析为治疗方案的选择提供了新方向，新型药物如BGB-3111、oprozomib等的临床试验相继开展，将为WM的治疗提供新的选择。就第58届美国血液学会（ASH）年会上关于WM的研究进展进行报道。

Progress in Waldenstrom macroglobulinemia

Waldenstrom macroglobulinemia (WM) is a malignant B-cell lymphoproliferative disorder, which still remains incurable. Reports on the latest research progress of WM were presented in the 58th American Society of Hematology (ASH) Annual Meeting, covering the theoretical and clinical researches of this disease. In basic research, mechanism of ibrutinib resistance has been further explored. The application of modern technologies, such as next-generation sequencing, has promoted the pathogenesis and prognosis of WM. In clinical research, retrospective analyses of traditional treatment provide new theoretical foundation in the choice of regimen, while clinical trials on new drugs including BGB-3111 and oprozomib may improve the therapy. The research advances in WM will be summarized in this paper.